Small Pharma

London, United Kingdom Founded: 2015 • Age: 11 yrs Minicorn Acquired By Cybin
Psychedelic-based therapeutics for mental health conditions are developed.

About Small Pharma

Small Pharma is a Healthcare company based in London (United Kingdom) founded in 2015, and was acquired by Cybin in August 2023. Psychedelic-based therapeutics for mental health conditions are developed. Small Pharma has raised $49.17 million across 7 funding rounds from investors including Gov.uk, Canaccord Genuity Group and Cybin. The company has 9 employees. Small Pharma was last valued at $4.19 million in July 2019. Small Pharma offers products and services including CYB003 and CYB004. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is SMALL PHARMA LTD.

Company details

Small Pharma was founded in 2015 in London, United Kingdom. Psychedelic-based therapeutics targeting mental health conditions are developed within the biotechnology sector. Tryptamine-based drug candidates are formulated using proprietary deuterium enriching technology. Operations center on advancing the pipeline, which includes SPL026, SPL028, SPL029, and SPL801 as injectable and oral DMT therapies for depressive disorder.

  • Headquarters London, United Kingdom
  • Employees 9
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website smallpharma.com
  • Social LinkedIn X Facebook Instagram
  • Acquired by Cybin (Aug 2023)
  • Legal Name Small Pharma Ltd
Operational Areas
Key Metrics
  • Annual Revenue
    $58.28 K (USD)
    -52
    as on Feb 28, 2021
  • Net Profit
    -$13.74 M (USD)
    -145
    as on Feb 28, 2022
  • EBITDA
    -$14.26 M (USD)
    -155
    as on Feb 28, 2022
  • Total Equity Funding
    $49.17M (USD)

    in 7 rounds

  • Latest Funding Round
    $46.02M (USD), Series A

    Mar 2021

  • Investors
    Gov.uk

    & 8 more

  • Employee Count
    9
  • Acquired by
    Cybin

    (Aug 2023)

Products & Services of Small Pharma

Small Pharma offers a comprehensive portfolio of products and services, including CYB003 and CYB004.

CYB003
Drug Therapy

Targets Major Depressive Disorder through psychedelic innovation

CYB004
Drug Therapy

Addresses Generalized Anxiety Disorder via novel formulations

Funding Insights of Small Pharma

Small Pharma has successfully raised a total of $49.17M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $46.02 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $49.17M
  • Total Rounds 7
  • Last Round Series A β€” $46.02M
  • First Round $125,666

    (Aug 2015)

  • Investors Count 8

All 7 funding rounds of Small Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2021$46.02MSeries A–Canaccord Genuity Group, Eight Capital
–
Jul 2019$911,679Seed$4.19MAI Fund, o2h ventures
–
Dec 2018$197,215Seed$3.37M–
–
Apr 2017$884,896Angel Round–Chris Torrance
Apr 2017$173,909Grant––
Feb 2017$1.03MSeed$‒‒‒‒‒–
–
Aug 2015$125,666Seed$‒‒‒‒‒–
–
Valuation history
DateValuationStage
Jul 2019$4.19Mβ€’β€’β€’β€’β€’β€’β€’β€’
Dec 2018$3.37Mβ€’β€’β€’β€’β€’β€’β€’β€’
Feb 2017$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Aug 2015$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Premium access

Full valuation and stage history of Small Pharma

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $4.19M (Jul 2019). 9 investors in total: 7 institutional and 2 angel.

Investors in Small Pharma

Small Pharma has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Gov.uk, Canaccord Genuity Group and Cybin.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
AI Fund is operated as a venture studio for AI startups.
aifund.aiMountain View, United States
Venture capital firm focused on angel investments
acfinvestors.comSheffield, United Kingdom
eight.capital
Invests in biotech therapeutics and AI technologies through EIS funds.
2014o2hventures.comCambridge, United Kingdom
Online government services and information are provided to users.
1707gov.ukLondon, United Kingdom
Merger and acquisitions advisory firm
1950canaccordgenuity.comToronto, Canada

Chris Torrance

Angel investor, ex-CEO of Pharmeasy, focused on healthcare and tech startups
unknown_d185ab8e01b54c4ba

Thomas Joseph Valentine

Angel investor and tech entrepreneur, co-founder of Secret Escapes, active in startups.
unknown_f9879fb9b9b140ea9
Psychedelic therapeutics for psychiatric disorders are developed and provided.
2002cybin.comToronto, Canada
Premium access

Investor details for Small Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Small Pharma

5 dated milestones of Small Pharma across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Small Pharma is founded.
  2. Funding First funding round of $126K.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Series A, of $46.0M.
  5. Exit Acquired by Cybin.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Small Pharma

Premium access

Complete news archive for Small Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Small Pharma

Small Pharma was founded in 2015.

Small Pharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Small Pharma is a funded company, having raised a total of $49.17M across 7 funding rounds to date. The company's 1st funding round was a Seed of $125.67K, raised on Aug 2015.

Small Pharma has 9 employees.

Annual revenue of Small Pharma is $58.28K as on Feb 28, 2021.

Small Pharma was founded in 2015 in London, United Kingdom. Psychedelic-based therapeutics targeting mental health conditions are developed within the biotechnology sector. Tryptamine-based drug candidates are formulated using proprietary deuterium enriching technology. Operations center on advancing the pipeline, which includes SPL026, SPL028, SPL029, and SPL801 as injectable and oral DMT therapies for depressive disorder.

Small Pharma offers CYB003 and CYB004.

Small Pharma has 9 investors. Key investors include Gov.uk, Canaccord Genuity Group, Cybin, AI Fund, and o2h ventures.

The valuation of Small Pharma is $4.19M as of Jul 2019.

Small Pharma operates through Small Pharma Ltd.

Yes. Small Pharma was acquired by Cybin in August 2023.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available